Johnson & Johnson (NYSE:JNJ) reported five-year CARTITUDE-2 study results showing that 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy after receiving a single infusion.
Johnson & Johnson (NYSE:JNJ) secured FDA De Novo authorization for its four-arm OTTAVA robotic surgical system.
Johnson & Johnson (NYSE:JNJ) has committed more than $1 billion to expand and modernize its Vision care operations in Jacksonville, Florida, targeting increased capacity for its market-leading ACUVUE®-brand contact lenses.
A Los Angeles County Superior Court jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $32 million to the family of a California woman who died from pleural mesothelioma, concluding that her fatal cancer was directly caused by decades of exposure to asbestos-contaminated talc in the company's iconic baby powder.
Johnson & Johnson (NYSE:JNJ) reported second-quarter sales of $25.3 billion alongside a reported earnings per share of $2.27.
